Listing 3 - Actual negotiations

Indication:

Fabry Disease

Indication:

For the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by a validated test, and who have received one or two prior systemic treatment regimens

Indication:

in combination with carboplatin and paclitaxel by public drug plans for the first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).

Indication:

For the treatment of patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation

Indication:

Multiple Indications

Indication:

Multiple Indications

Indication:

Giant Cell Arteritis

Indication:

For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.

Indication:

Testosterone replacement therapy

Indication:

For the treatment of adult patients with Cushing's disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option.